Table 3. Association of the smoking status, lesion subtype and baseline BCVA with BCVA at month 6.
|
Potential variables |
p values |
|||
|
Smoking status |
Never smoked |
Ex-smokers |
Current smokers |
|
| Number of cases |
41 |
17 |
44 |
|
| Mean baseline BCVA |
0.99±0.53 |
0.70±0.62 |
0.97±0.61 |
0.19/ 0.96 |
| Mean BCVA improvement |
0.06±0.37 |
0.15±0.31 |
0.07±0.36 |
0.63/ 0.80 |
|
Lesion subtype |
Typical nAMD |
PCV |
||
| Number of cases |
70 |
32 |
||
| Mean baseline BCVA |
0.90±0.57 |
1.00±0.63 |
0.44 |
|
| Mean BCVA improvement |
0.10±0.35 |
0.00±0.32 |
0.42 |
|
|
Baseline visual acuity |
<20/100 |
20≥100 |
||
| Number of cases |
55 |
47 |
||
| Mean baseline BCVA |
1.05±0.62 |
0.80±0.53 |
0.04 |
|
| Mean BCVA improvement | 0.11±0.37 | 0.04±0.34 | 0.28 | |
Never smoked is the reference category (one-way ANOVA). BCVA=best-corrected visual acuity, LogMAR vision; nAMD=neovascular age-related macular degeneration; PCV=polypoidal choroidal vasculopathy